



Erratum to lipid mediator lipoxin A4 and its analog BML-111 exert antitumor effects in melanoma

Editorial Office

Annals of Translational Medicine

Correspondence to: Editorial Office. Annals of Translational Medicine. Email: editor@atmjournals.org.

Submitted Feb 10, 2022. Accepted for publication Mar 04, 2022.

doi: 10.21037/atm-2022-6

View this article at: <https://dx.doi.org/10.21037/atm-2022-6>

Erratum to: Ann Transl Med 2021;9:802

In the article (1) entitled “Lipid mediator lipoxin A4 and its analog BML-111 exert antitumor effects in melanoma” (doi:10.21037/atm-21-1873), the fourth author “Zhu Shen” should be removed from the authorship and the authorship should be corrected as follows: Yu Du^{1,2#}, Jianing Yang^{2,3#}, Tangfeng Su^{4#}, Juan Li^{2,3}. The author’s affiliation remain intact and the author contribution should be corrected as: (I) Conception and design: J Li; (II) Administrative support: None; (III) Provision of study materials or patients: J Yang; (IV) Collection and assembly of data: Y Du; (V) Data analysis and interpretation: T Su; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

The authors regret the error due to a lack of communication before publication by listing Zhu Shen in the authorship without his consent.

The authors confirmed this error did not affect either the results or the conclusions of the paper.

Below is the correct authorship information:

Yu Du^{1,2#}, Jianing Yang^{2,3#}, Tangfeng Su^{4#}, Juan Li^{2,3}

¹Department of Anesthesiology, Sichuan Provincial People’s Hospital, University of Electronic and Technology of China, Chengdu, China; ²Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China; ³Department of Dermatology, Sichuan Provincial People’s Hospital, University of Electronic and Technology of China, Chengdu, China; ⁴Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Contributions: (I) Conception and design: J Li; (II) Administrative support: None; (III) Provision of study materials or patients: J Yang; (IV) Collection and assembly of data: Y Du; (V) Data analysis and interpretation: T Su; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Click [here](#) to view the updated version of the article.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Du Y, Yang J, Su T, et al. Lipid mediator lipoxin A4 and its analog BML-111 exert antitumor effects in melanoma. *Ann Transl Med* 2021;9:802.

Cite this article as: Editorial Office. Erratum to lipid mediator lipoxin A4 and its analog BML-111 exert antitumor effects in melanoma. *Ann Transl Med* 2022;10(7):428. doi: 10.21037/atm-2022-6